The melanoma clinical will be only a proof of concept, so it won't be necessary to have a large sample size for each PD-1(L) inhibitor.
So I guess each one that has shown promise in the preclinical will be included in the clinical.
The target audience is BP, not the FDA.
Industry news, page-439
-
- There are more pages in this discussion • 1,331 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.76 |
Change
0.050(2.92%) |
Mkt cap ! $311.6M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.96 | $1.75 | $697.2K | 375.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3727 | $1.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.80 | 2259 | 1 |
View Market Depth
| Last trade - 12.43pm 26/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |